Abstract:Fabrizio Martora, 1 Claudio Marasca, 2 Sara Cacciapuoti, 1 Federica Fariello, 1 Luca Potestio, 1 Teresa Battista, 1 Massimiliano Scalvenzi, 1 Matteo Megna 1 1 Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 2 Dermatology Unit, Medical Department, "Antonio Cardarelli" National Hospital, Naples, Italy Correspondence: Fabrizio Martora, Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Naples, 80131, Italy, Tel +39 - 081 – 7462457, Fax +39 - 081 – 7462442, Email Background: The treatment of hidradenitis suppurativa (HS) has always been a real challenge for dermatologists; to date, adalimumab the only biologic drug approved for HS is adalimumab, an anti-tumor necrosis factor (TNF)-α drug, the approval of this drug dates to 2015, data provided by real life show an effectiveness rate of about 60% percent. Recently (31 October 2023) FDA approves secukinumab for moderate-severe HS. The treatment and management of HS is very challenging as available treatments are very limited and show very variable outcomes. Methods: We conducted a prospective monocentric study designed to evaluate the efficacy and safety of secukinumab treatment in HS patients in a real-life setting. Results: The initial cohort of patients recruited included 21 HS patients including 12 females and 9 males. About 57.1% of patients achieved the primary endpoint and recorded significant decrease in all the severity assessment scales (IHS4, DLQI and VAS pain scale) at week 16 and 52, when HiSCR reached 71.4%. Conclusion: The results of our study highlight that treatment with secukinumab in patients with severe HS who failed adalimumab may be a safe and effective therapeutic weapon. Keywords: hidradenitis suppurativa, secukinumab, adalimumab, treatments Hidradenitis suppurativa (HS), is a chronic, inflammatory, recurrent and debilitating skin disease affecting hair follicles, the manifestations are characterized by inflammatory, painful and localized lesions in body districts where apocrine glands are present. 1,2 The underlying pathogenic mechanism of HS is not yet known certainly follicular hyperkeratosis within the pilosebaceous-apocrine unit represents the initial lesion. New studies show new insights into the role of pro-inflammatory cytokines in the pathogenesis of HS, helping to fill some existing gaps in the knowledge of the development of this pathology. 3,4 The treatment of HS has always been a real challenge for dermatologists; to date, the first FDA biologic drug approved for HS is adalimumab, an anti-tumor necrosis factor (TNF)-α drug, whose approval dates to 2015. Several real-life studies highlight a mean clinical success rate of about 60%. 5–8 However, primary or secondary lack of efficacy may occur. 9–13 Secukinumab, an anti-interleukin 17A drug approved for moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis has shown effective results in clinical trials improving signs and symptoms of HS with a good safety profile and response up to 52 weeks. 14 Even few real-life data are already in line with the studies carried out. 14 Recently, European Commission (EC) has approved secukinumab, for use in adults with active moderate to severe HS and an inadequate response to conventional systemic HS therapy, 15 while FDA approval has been reached recently (31 October 2023). The treatment and management of HS is very challenging as available treatments are very limited and show very variable outcomes. Indeed, different new drugs are being tested for HS (eg, spesolimab and porvocitinib). It is therefore important for the future to select new therapeutic targets for HS establishing a universally and shared treatment algorithm. Among future drugs, secukinumab certainly represents the most immediate novelty. We conducted a prospective monocentric study designed to evaluate the efficacy and safety of secukinumab treatment in HS patients in a real-life setting. The inclusion criteria followed the criteria established during the clinical trials conducted for HS. 15,16 Inclusion criteria were: i) age ≥ 18 years; ii) diagnosis of moderate to severe HS (Hurley II or III); particularly eligible patients were required to be diagnosed at least 1 year before the baseline visit and have a total abscess and inflammatory nodule (AN) count ≥ 3 at baseline, HS lesions in ≥ 2 distinct anatomical locations, a draining fistula count ≤ 20 at baseline, and inadequate response to oral antibiotics for the treatment of HS. iii) Adalimumab primary or -Abstract Truncated-

Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study

Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study

Anti-IL17 Secukinumab in hidradenitis suppurativa: A long-term drug survival analysis

Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study

Secukinumab in patients with moderate to severe hidradenitis suppurativa based on prior biologic exposure: An efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials

Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials

New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials

An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa

Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis

Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape

Real‐world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study

Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa

The Efficacy and Safety of Biosimilars in Hidradenitis Suppurativa: A Comprehensive Review

The most recent advances in understanding and managing hidradenitis suppurativa

P230 Clinical characteristics, risk factors and management of patients with inflammatory bowel disease and hidradenitis suppurativa: a nationwide multicenter study of the GETECCU ENEIDA registry

B-cell and complement signature in severe hidradenitis suppurativa that does not respond to adalimumab

Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled clinical trial

Brodalumab for moderate–severe hidradenitis suppurativa: An open‐label multicentric cohort study in real clinical practice

Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa

Assessing the Role of Adalimumab in Treating Hidradenitis Suppurativa: Findings from a Retrospective Study at a Reference Center